GHP Investment Advisors Inc. Increases Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

GHP Investment Advisors Inc. grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.1% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 11,354 shares of the biopharmaceutical company’s stock after purchasing an additional 122 shares during the quarter. GHP Investment Advisors Inc.’s holdings in Gilead Sciences were worth $1,049,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the business. FMR LLC raised its position in Gilead Sciences by 79.4% in the third quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company’s stock worth $2,780,329,000 after acquiring an additional 14,680,161 shares during the period. Wellington Management Group LLP increased its position in Gilead Sciences by 50.9% in the third quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company’s stock worth $2,900,921,000 after buying an additional 11,665,593 shares in the last quarter. Pacer Advisors Inc. raised its stake in shares of Gilead Sciences by 723.3% in the fourth quarter. Pacer Advisors Inc. now owns 6,434,665 shares of the biopharmaceutical company’s stock worth $594,370,000 after buying an additional 5,653,075 shares during the period. Point72 Asset Management L.P. lifted its position in shares of Gilead Sciences by 350.1% during the 3rd quarter. Point72 Asset Management L.P. now owns 2,305,270 shares of the biopharmaceutical company’s stock valued at $193,274,000 after buying an additional 1,793,145 shares in the last quarter. Finally, International Assets Investment Management LLC grew its stake in shares of Gilead Sciences by 8,238.4% during the 3rd quarter. International Assets Investment Management LLC now owns 1,642,504 shares of the biopharmaceutical company’s stock valued at $137,708,000 after acquiring an additional 1,622,806 shares during the period. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Trading Down 2.0 %

GILD stock opened at $96.04 on Friday. The firm’s fifty day simple moving average is $92.97 and its two-hundred day simple moving average is $86.49. The stock has a market capitalization of $119.69 billion, a price-to-earnings ratio of 1,067.11, a price-to-earnings-growth ratio of 1.37 and a beta of 0.18. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $100.51.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The business had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. During the same quarter last year, the firm earned $2.29 earnings per share. The firm’s quarterly revenue was up 7.0% compared to the same quarter last year. As a group, analysts anticipate that Gilead Sciences, Inc. will post 4.34 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the stock. Oppenheimer lifted their price target on shares of Gilead Sciences from $105.00 to $115.00 and gave the company an “outperform” rating in a report on Tuesday, December 10th. Truist Financial upped their target price on shares of Gilead Sciences from $83.00 to $97.00 and gave the stock a “hold” rating in a report on Friday, November 8th. Citigroup started coverage on Gilead Sciences in a report on Thursday, November 14th. They set a “buy” rating and a $125.00 price target on the stock. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $84.00 price objective on shares of Gilead Sciences in a research note on Monday, February 3rd. Finally, The Goldman Sachs Group lifted their target price on Gilead Sciences from $74.00 to $84.00 and gave the company a “neutral” rating in a research note on Thursday, November 7th. Eleven research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have given a strong buy rating to the stock. According to data from MarketBeat.com, Gilead Sciences presently has an average rating of “Moderate Buy” and a consensus target price of $98.39.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 248,645 shares of Gilead Sciences stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $92.76, for a total value of $23,064,310.20. Following the completion of the sale, the chief financial officer now directly owns 138,919 shares in the company, valued at $12,886,126.44. The trade was a 64.16 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Merdad Parsey sold 164,211 shares of the firm’s stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the transaction, the insider now directly owns 80,801 shares in the company, valued at $7,427,227.92. This trade represents a 67.02 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 572,824 shares of company stock valued at $53,611,715. Insiders own 0.29% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.